Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Infectious Diseases

• Publication date

  2002-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/340861PMID 12087527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions

  2001cited by this paper
• Risk Assessment for Antimicrobial Agent‐Induced QTc Interval Prolongation and Torsades de Pointes

  2001cited by this paper
• Contraindicated use of cisapride: impact of food and drug administration regulatory action.

  2000cited by this paper
• Risk of torsades de pointes with non-cardiac drugs

  2000cited by this paper
• Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.

  2000cited by this paper
• The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.

  2000cited by this paper
• Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.

  1993cited by this paper
• Drug-induced torsades de pointes

  1986cited by this paper

• Macrolide Antibiotic Mediated Cardiac Arrhythmias: Emerging Concepts and Clinical Implications

  2025cites this paper
• Mycoplasma pneumonia: Modern antibacterial therapy

  2025cites this paper
• Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients

  2024cites this paper
• Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit

  2024cites this paper
• Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study

  2023cites this paper
• Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity

  2023cites this paper
• A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease

  2022cites this paper
• Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin

  2022cites this paper
• Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study

  2021cites this paper
• Enteral and Parenteral Antimicrobials Used in the SDD Policy

  2021cites this paper
• Bactericidal and Bacteriostatic Antibiotics

  2021cites this paper
• Detecting drug‐drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system

  2021cites this paper
• Drug-induced long qt syndrome

  2020cites this paper
• Eventos cardiovasculares relacionados con el uso de macrólidos en una unidad de cuidado intensivo

  2020cites this paper
• Cardiovascular side-effects of common antibiotics

  2020cites this paper
• Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines

  2020cites this paper
• British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease

  2020cites this paper
• Association of Azithromycin Use With Cardiovascular Mortality

  2020cites this paper
• Bioavailability of Antibiotics and Their Toxicity

  2020cites this paper
• Comparative Study of the Effect of Macrolide Antibiotics Erythromycin, Clarithromycin, and Azithromycin on the ERG1 Gene Expression in H9c2 Cardiomyoblast Cells

  2020cites this paper
• Antibiotics and Antimicrobial Resistance Genes: Environmental Occurrence and Treatment Technologies

  2020cites this paper
• Cardiovascular events related to the use of macrolides in an intensive care unit

  2020cites this paper
• Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis.

  2020cites this paper
• Cardiovascular safety of macrolide and fluoroquinolone antibiotics: An analysis of the WHO database of adverse drug reactions

  2019cites this paper
• Approach to initiating QT-prolonging oncology drugs in the ambulatory setting

  2019cites this paper
• PREVALENCE AND DETERMINANTS OF ANTIBIOTIC RELATED ADVERSE DRUG REACTIONS IN KENYA : SPONTANEOUSLY REPORTED CASES AT THE PHARMACY AND POISONS BOARD DATABASE

  2018cites this paper
• Risks associated with the use of fluoroquinolones.

  2018cites this paper
• Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies

  2017cites this paper
• Macrolide maintenance treatment for bronchiectasis

  2017cites this paper
• The impact of fever on corrected QT interval.

  2017cites this paper
• Appraisal of the cardiovascular risks of azithromycin: an observational analysis.

  2017cites this paper
• Is cardiovascular risk a concern when prescribing azithromycin?

  2017cites this paper
• Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports

  2017cites this paper
• Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review

  2017cites this paper
• Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study

  2017cites this paper
• Use of azithromycin and risk of ventricular arrhythmia

  2017cites this paper
• Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes

  2016cites this paper
• Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosis

  2016cites this paper
• Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events

  2016cites this paper
• Immunomodulatory effects of macrolide antibiotics – part 2: advantages and disadvantage of macrolide maintenance therapy

  2016cites this paper
• Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study

  2016cites this paper
• Drug-induced QT interval prolongation and torsades de pointes

  2016cites this paper
• Macrolides use and the risk of sudden cardiac death

  2016cites this paper
• Antibiotic interactions: Answers to 4 common questions.

  2016cites this paper
• Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials

  2016cites this paper
• 29 – Macrolides, Clindamycin, and Ketolides

  2015cites this paper
• Prolongacion del intervalo QT inducido por farmacos: ? sus riesgos?

  2015cites this paper
• Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors

  2015cites this paper
• Behandlung postoperativer Passagestörungen, Cholangitis und Pankreatitis

  2015cites this paper
• [Drug-induced QT interval prolongation: do we know the risks?].

  2015cites this paper
• Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics

  2015cites this paper
• Behandlung postoperativer Passagestörungen, Cholangitis und Pankreatitis

  2015cites this paper
• Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos?

  2015cites this paper
• [Treatment of postoperative impairment of gastrointestinal motility, cholangitis and pancreatitis].

  2015cites this paper
• Cardiac risks associated with antibiotics: azithromycin and levofloxacin

  2015influential citation
• Drug-induced QT interval prolongation: Do we know the risks?

  2015cites this paper
• Cardiovascular Toxicity of Noncardiovascular Drugs

  2015cites this paper
• Multiple accessory pathways in a patient with congenitally corrected transposition of the great arteries and severe malformation of the coronary sinus.

  2014cites this paper
• Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study

  2014cites this paper
• Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients

  2014cites this paper
• Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity

  2014influential citation
• Antibiotic-induced cardiac arrhythmias.

  2014cites this paper
• The role of macrolides in asthma: current evidence and future directions.

  2014cites this paper
• A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?

  2014influential citation
• Care Transitions: A Leverage Point for Safe and Effective Medication Use in Older Adults - A Mini-Review

  2014cites this paper
• Effects of macrolide antibiotics on rat embryonic heart function in vitro.

  2014cites this paper
• Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.

  2014cites this paper
• Acquired Long QT Syndrome: A Focus for the General Pediatrician

  2014cites this paper
• The cardiotoxicity of macrolides: the role of interactions

  2013cites this paper
• Use of azithromycin and death from cardiovascular causes.

  2013cites this paper
• Preventing COPD exacerbations with macrolides: a review and budget impact analysis.

  2013cites this paper
• Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused?

  2013cites this paper
• Détermination et optimisation du contenu gastrique en anesthésie

  2013cites this paper
• Therapeutic Advances in Infectious Disease

  2013influential citation
• Syncope and polymorphic ventricular tachycardia in the setting of a febrile illness.

  2013cites this paper
• Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports

  2013influential citation
• Multiple accessory pathways in a patient with congenitally corrected transposition of the great arteries and severe malformation of the coronary sinus

  2013cites this paper
• Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database

  2013cites this paper
• Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused?

  2013cites this paper
• Drug-Induced Cardiovascular Adverse Events in the Intensive Care Unit

  2013cites this paper
• Navigating the Future Path of Cardiac Drug Safety

  2012cites this paper
• QT Prolongation with Antimicrobial Agents

  2012cites this paper
• Azithromycin and the risk of cardiovascular death.

  2012cites this paper
• Diurnal Differences in Common Electrocardiographic Indices of Arrhythmic Liability in Normal Telemetered Dogs and Telemetered Dogs with Failing Hearts: Implications for Safety Pharmacology and Veterinary Cardiology

  2011cites this paper
• Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

  2011cites this paper
• Macrolides, Azalides, and Ketolides

  2011cites this paper
• QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications

  2011cites this paper
• QTc prolongation in the intensive care unit: a review of offending agents.

  2011cites this paper
• KUCERS ' THE USE OF ANTIBIOTICS A CLINICAL REVIEW OF ANTIBACTERIAL , ANTIFUNGAL , ANTIPARASITIC AND ANTIVIRAL DRUGS VOLUME 1 6

  2011cites this paper
• Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

  2010cites this paper
• Oritavancin, a New Lipoglycopeptide Antibiotic: Results From a Thorough QT Study

  2010cites this paper
• Torsades: adjacent and triggering electrocardiographic events.

  2010cites this paper
• QT prolongation in the intensive care unit: commonly used medications and the impact of drug–drug interactions

  2010cites this paper
• Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

  2010cites this paper
• Advantages of Azithromycin Over Erythromycin in Improving the Gastric Emptying Half-Time in Adult Patients With Gastroparesis

  2010cites this paper
• Antimicrobials and the Risk of Torsades de Pointes

  2010cites this paper
• Antimicrobial agents-associated with QT interval prolongation.

  2010cites this paper
• Drug‐Induced QT‐Interval Prolongation: Considerations for Clinicians

  2010cites this paper
• Erythromycin as a prokinetic agent: risk factors.

  2010cites this paper
• and the International Society for Computerized Electrocardiology Endorsed by the American Association of Critical-Care Nurses Foundation Cardiology From the American Heart Association and the American College of Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement

  2010cites this paper